SARS-CoV-2 Antibodies Detection Kit (Latex particle-enhanced
turbidimetric immunoassay)
Product information
Product name | SARS-CoV-2 Antibodies Detection Kit (Latex particle-enhanced
turbidimetric immunoassay) |
Application | Qualitative and semi-quantitative detection of antibodies to
SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human
serum . |
Specimen | Serum |
Usage | For in vitro diagnostic use |
Model | K218-200 |
Brand | KISSH |
Product Description
SARS-CoV-2 Antibodies Test Kit(Latex particle-enhanced
turbidimetric immunoassay) is intended for qualitative and
semi-quantitative detection of antibodies to SARS-CoV-2 spike (S)
protein receptor binding domain (RBD) in human serum .
SARS-CoV-2, the causative agent of Coronavirus Disease 2019
(COVID-19), is an enveloped, single-stranded RNA Betacoronavirus. 7
coronaviruses have been identified as agents of human infection,
causing disease ranging from mild common cold to severe respiratory
failure.
SARS-CoV-2 is transmitted primarily from person-to-person through
respiratory droplets and aerosols. The incubation period from
infection to detectable viral load in the host commonly ranges from
2 to 14 days. Detection of viral load can be associated with the
onset of clinical signs and symptoms, although a considerable
proportion of individuals remains asymptomatic or mildly
symptomatic. The interval during which an individual with COVID-19
is infectious has not yet been clearly established, however,
transmission from symptomatic, asymptomatic, and pre-symptomatic
individuals has been well described. Coronavirus genomes encode 4
main structural proteins: spike (S), envelope (E), membrane (M),
and nucleocapsid (N). The S protein is a very large transmembrane
protein that assembles into trimers to form the distinctive surface
spikes of coronaviruses. Each S monomer consists of an N-terminal
S1 domain and a membrane-proximal S2 domain. The virus gains entry
to the host cell through binding of the S protein to the
angiotensin-converting enzyme 2 (ACE2), which is enzymatically
active on the surface of numerous cell types including the alveolar
type II cells of the lung and epithelial cells of the oral mucosa.
Mechanistically, ACE2 is engaged by the receptor-binding domain
(RBD) on the S1 subunit.
Upon infection with SARS-CoV-2, the host mounts an immune response
against the virus, typically including production of specific
antibodies against viral antigens. IgM and IgG antibodies to
SARS-CoV-2 appear to arise nearly simultaneously in blood.There is
significant inter-individual difference in the levels and
chronological appearance of antibodies in COVID-19 patients, but
median seroconversion has been observed at approximately 2 weeks.
Serologic assays can play an important role in understanding viral
epidemiology in the general population. The SARS-CoV-2 Antibodies
Test Kit(Latex particle-enhanced turbidimetric immunoassay) uses a
recombinant protein representing the RBD of the S antigen .
